Cash and cash equivalents of $131.7 million at December 31, 2025 compared to $102.6 million at September 30, 2025. The Company anticipates at its current cash utilization rate, an approximate cash runway of more than 3 years.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- AVXL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Anavex joins ACCESS-AD, initiative for therapeutic approaches for Alzheimer’s
- Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron
- Anavex receives FDA feedback on Alzheimer’s disease program
- Anavex submits request for EMA to re-examine its opinion on blarcamesine